For Immediate Release
Chicago, IL – July 9, 2013 – Zacks Equity Research highlights Valeant Pharmaceuticals (VRX-Free Report) as the Bull of the Day and Yamana Gold (AUY-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on the Helen of Troy Limited (HELE-Free Report), Inter Parfums Inc. (IPAR-Free Report) and Elizabeth Arden Inc. (RDEN-Free Report).
Here is a synopsis of all five stocks:
Valeant Pharmaceuticals (VRX-Free Report), Zacks Rank #1, is a healthcare provider with a focus on dermatology and eye care products. Valeant may provide a remedy for investors looking for growth in a macro environment filled with unease over higher interest rates, slow economic growth, and geopolitical strain. Interest rates have shot higher in recent weeks on firm U.S. labor market conditions and ideas the Federal Reserve could taper its asset purchase program in September, while the IMF recently hinted it could cut its global growth forecast due to the weak performance in emerging market economies. These dynamics are mixed social unrest in Egypt. Demand for healthcare products should be insulated from these macro dynamics, and growth shares in the healthcare sector may provide refuge for investors trying to avoid the pot holes of higher rates and slow global growth.
Valeant has produced vibrant revenue growth in recent years helped by an aggressive acquisition strategy. Valeant made 11 acquisitions in 2011 and another 12 in 2012. These actions helped to propel 108% revenue growth in 2011 and another 44% in 2012. In Late May, Valeant announced the purchase of Bausch and Lomb. The deal is expected to generate $800 mln in cost savings, an internal rate of return in excess of 20%, and be accretive to earnings. In a recent company presentation, Valeant highlighted an aging population, increased incidence of diabetes, and rising wealth in emerging nations as factors which will support growth in ophthalmology.
Of the nine analysts covering Valeant, five have moved their 2013 and 2014 earnings per share estimates higher in the past quarter. At the same time, the consensus earnings per share estimates for 2013 and 2014 have increased $0.29 and $1.39 to $5.93 and $7.92 respectively over the past quarter.
Investors have been fleeing gold investments this year, and the tarnish on the yellow metal has spilled into gold stocks. Yamana Gold (AUY-Free Report), Zacks Rank #5, is a Canadian gold producer with operations in the Americas and has been a causality of the bear market in gold. Investors should look to mine for profits elsewhere.
Of the ten analysts covering Yamana, six have cut their profit estimate over the past 60 days. The consensus outlook for 2013 earnings per share has declined from $0.85 to $0.68 or 20% over the same period. Furthermore, the most accurate forecaster of earnings for Yamana is more pessimistic than the consensus looking for 2013 earnings per share at $0.49, which is about 28% below the consensus view of $0.68.
This raises the prospect for a downside earnings surprise. The weak trend in earnings estimates bodes poorly for Yamana which has already missed profit estimate four of the past five quarters. A firm dollar, higher treasury yields, strong equity returns, and talk of the Federal Reserve tapering its asset purchase program have created a bearish cocktail for the gold market and a headwind to the outlook for Yamana’s profits.
Furthermore, India has historically been a large buyer of gold, but the weakness in the Indian rupee has hurt the purchasing power of the Indian consumer. The Indian government has implemented measures to restrict gold imports in order to reduce India’s current account deficit and the Central Bank of India has curbed the use of credit cards for the purchase of gold items, including jewelry. Investor distaste for gold may be seen in the liquidation of gold held by the SPDR Gold ETF. Gold holdings have declined by almost 389 tons or 28.7% since the end of 2012. At 962 tons, holdings are at their lowest level since February 2009.
Helen of Troy Downgraded to Strong Sell
On Jul 6, 2013, Zacks Investment Research downgraded the global consumer products company, Helen of Troy Limited (HELE-Free Report), to a Zacks Rank #5 (Strong Sell). The downgrade was based on the company’s disappointing outlook for fiscal 2014 and tough macroeconomic conditions and higher costs lying ahead for the company.
Why the Downgrade?
On Apr 29, 2013, at its fourth-quarter fiscal 2013 conference call Helen of Troy provided a conservative fiscal 2014 guidance due to a tough retail environment and a conservative approach to the cold/cough/flu season. Further, management expects that the product costs will increase across all segments during fiscal 2014.
We expect that the company will incur high costs as it transitions to the new 1.3 million square foot distribution facility in Olive Branch, MS, to accommodate anticipated future growth.
Further, in the Personal Care segment Helen of Troy expects sales to decrease in fiscal 2014 due to the stiff competition in the liquids area. Some of its major competitors have launched shampoo lines that are competing directly with those of Helen of Troy. In fact, the Personal Care segment has been consistently reporting sluggish growth for several quarters mainly due to difficult U.S. retail sales environment in the grooming, skin care and hair care category.
Estimates mostly moved downwards following the discouraging guidance provided by the company for the fiscal 2014. The Zacks Consensus Estimate for fiscal 2014 fell 7.9% to $3.55 over the last 90 days. Similarly, the Zacks Consensus Estimate for fiscal 2015 fell 18.0% to $3.27 over the same period.
The company has missed estimates in two of the past four quarters. Moreover, though it beat the Zacks Consensus Estimate in the fourth quarter it was only because of tight cost control. The top line results were not strong enough – thus signaling lack of growth.
Other Stocks to Consider:
Others players in the same industry which look attractive at the current levels include Inter Parfums Inc. (IPAR-Free Report) and Elizabeth Arden Inc. (RDEN-Free Report). While Inter Parfums carries a Zacks Rank #1 (Strong Buy), Elizabeth Arden holds a Zacks Rank #2 (Buy).
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
More From Zacks.com
- Personal Investing Ideas & Strategies
- Valeant Pharmaceuticals
- Yamana Gold
- Zacks Investment Research
- Helen of Troy Limited
- Elizabeth Arden